Efficacy and Safety of T1225 1.5% Versus Tobramycin 0.3 % in the Treatment of Purulent Bacterial Conjunctivitis

Inclusion Criteria: * Male or female \>= 1 day old (newborn, infant, child, adult); * written informed consent by patient or legally acceptable representative; * purulent bacterial conjunctivitis (unilateral or bilateral) defined as bulbar conjunctival injection (mild, moderate, or severe) AND conjunctival purulent discharge (mild, moderate or severe). Exclusion Criteria: * Bacterial conjunctivitis diagnosed \>= 7 days ago; * bacterial infection due to trauma or foreign body; * dacryocystitis; * corneal ulceration or keratitis; * viral ocular infection; closed angle glaucoma; * acute allergy conjunctivitis; * clinically significant ocular abnormality; * organic amblyopia, monophthalmia; * corrected visual acuity below 20/100; * contact lens wearer; * newborn (i.e. 0-2 months old) not born at term (\< 37 weeks of amenorrhea); * ocular surgery, laser in situ keratomileusis (LASIK), laser epithelial keratomileusis (LASEK), or photo-refractive keratectomy (PRK) in last 12 months; * ocular laser treatment in last 3 months; * systemic macrolide antibiotics in last month; * systemic steroids in last 2 weeks or during the study; * topical ocular macrolide antibiotics and/or topical ocular steroids and/or non-steroidal anti-inflammatory drugs (NSAIDs) in last week; * topical (ocular, nasal, bronchial etc.) treatments and/or systemic NSAIDs in last day; * immunosuppressives and/or any systemic antibiotic on D0.